Theralase release's 3q2023 interim financial statements

Toronto, on / accesswire / november 29, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") for the safe and effective destruction of various cancers, bacteria and viruses has released the company's 3q2023 unaudited condensed interim consolidated financial statements ("financial statements"). financial summary: for the nine-month period ended september 30th: 1 other represents foreign exchange, interest accretion on lease liabilities and / or interest income financial highlights for the nine-month period ended september 30 th , 2023: total revenue decreased 13%, year over year.
CAN Ratings Summary
CAN Quant Ranking